Tyra Biosciences, Inc.

Tyra Biosciences, Inc.

TYRA·NASDAQ

$27.18

-5.3%
HealthcareBiotechnology

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

At a Glance

Live Snapshot
Market Cap$1.62B
EPS-2.0100
P/E Ratio-13.52
Earnings Date08/06/2026

tyra

Sales/Maturities of Investments

Last Annual Value

173.86M

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Tyra Biosciences, Inc.

Tyra Biosciences, Inc. Competitors Analysis of Sales/Maturities of Investments

TYRA · NASDAQ
CompanySales/Maturities of Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
173.86M
N/AN/AN/A 
SVRA logo
Savara Inc.
NASDAQ:SVRA
182.20M
9.9%14.7%28.2%
PROK logo
ProKidney Corp.
NASDAQ:PROK
318.02M
21.8%N/AN/A
755.13M
21.1%18.7%27.1%
101.18M
-8.6%50.7%N/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
113.60M
166.5%N/AN/A
0.00
N/AN/AN/A
318.90M
79.3%N/A37.5%
411.72M
11.6%10.5%11.5%
874.25M
15.0%N/AN/A
Tyra Biosciences, Inc.

Tyra Biosciences, Inc. Fair Value Envelope

TYRA · NASDAQ

Our analysis suggests that TYRA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $27.18, this represents a potential HIDDEN relative to our calculated worth for Tyra Biosciences, Inc..

Intrinsic Value
Current Price: $27.18